Andreja Trpkovic, Edith Stokic, Djordje Radak, Zoran Gluvic, Mohamed Haidara, Dimitri P. Mikhailidis and Esma R. Isenovic Pages 3823 - 3829 ( 7 )
The role of hepatitis C virus (HCV) infection in the development of vascular disease is controversial. Insulin resistance (IR) is a recognized risk factor for cardiovascular disease (CVD) and is associated with chronic hepatitis C (CHC). Thus, IR may promote atherosclerosis and vascular disease in CHC patients. HCV-associated IR may also cause hepatic steatosis and resistance to antiviral treatment. In addition, HCV may contribute a direct, proatherogenetic action on the vascular wall. This review considers the impact of IR on interferon-α based therapy of HCV infection and the role of insulin-sensitizing agents on the response to antiviral treatment and prevention of IR complications, including CVD.
Hepatitis C,insulin resistance,interferon-α,vascular disease,oxidative stress,Interferon (INF),interferon-receptor,Jak/STAT,ISGF3,HOMA-IR,SOCS3,protein phosphatase 2A,PIAS1,protein arginine methyl-transferase (PRMT1),B kinase-beta (IKK),Etanercept,TNF-protein,T1DM,T2DM,HEPATIC STEATOSIS (HS),metabolic steatosis,non alcoholic fatty liver disease,Thiazolidinediones,pioglitazone,rosiglitazone,peroxisome proliferator activated receptors,PPAR- mRNA,STATIN THERAPY AND CHC
, , , , , , Institute Vinca, Laboratory for Molecular Genetics and Radiobiology, PO Box 522, 11001 Belgrade Serbia.